Peter Svennilson - Net Worth and Insider Trading

Peter Svennilson Net Worth

The estimated net worth of Peter Svennilson is at least $357 Million dollars as of 2024-11-13. Peter Svennilson is the Director of Revolution Medicines Inc and owns about 4,737,523 shares of Revolution Medicines Inc (RVMD) stock worth over $281 Million. Peter Svennilson is the Director, 10% Owner of Immune Design Corp and owns about 6,642,942 shares of Immune Design Corp (IMDZ) stock worth over $39 Million. Peter Svennilson is also the Director, 10% Owner of NGM Biopharmaceuticals Inc and owns about 17,726,978 shares of NGM Biopharmaceuticals Inc (NGM) stock worth over $27 Million. Besides these, Peter Svennilson also holds RAPT Therapeutics Inc (RAPT) . Details can be seen in Peter Svennilson's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Peter Svennilson has not made any transactions after 2021-04-28 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Peter Svennilson

Peter Svennilson Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Peter Svennilson owns 10 companies in total, including RAPT Therapeutics Inc (RAPT) , NGM Biopharmaceuticals Inc (NGM) , and Nurix Therapeutics Inc (NRIX) among others .

Click here to see the complete history of Peter Svennilson’s form 4 insider trades.

Insider Ownership Summary of Peter Svennilson

Ticker	Comapny	Transaction Date	Type of Owner
RAPT	RAPT Therapeutics Inc	2021-08-18	10 percent owner
NGM	NGM Biopharmaceuticals Inc	2020-04-08	director & 10 percent owner
NRIX	Nurix Therapeutics Inc	2021-05-07	10 percent owner
		2021-04-28	director & 10 percent owner
		2021-11-12	10 percent owner
		2020-03-19	10 percent owner & other: Managing Partner
		2018-09-27	director & 10 percent owner
		2019-04-02	10 percent owner & other: Managing Partner
		2018-03-14	10 percent owner
		2021-08-25	10 percent owner

Peter Svennilson Latest Holdings Summary

Peter Svennilson currently owns a total of 4 stocks. Among these stocks, Peter Svennilson owns 4,737,523 shares of Revolution Medicines Inc (RVMD) as of April 28, 2021, with a value of $281 Million and a weighting of 78.77%. Peter Svennilson owns 6,642,942 shares of Immune Design Corp (IMDZ) as of October 27, 2017, with a value of $39 Million and a weighting of 10.89%. Peter Svennilson also owns 17,726,978 shares of NGM Biopharmaceuticals Inc (NGM) as of April 8, 2020, with a value of $27 Million and a weighting of 7.65%. The other 1 stocks RAPT Therapeutics Inc (RAPT) have a combined weighting of 2.7% among all his current holdings.

Latest Holdings of Peter Svennilson

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
RVMD	Revolution Medicines Inc	2021-04-28	4,737,523	59.36	281,219,365
IMDZ	Immune Design Corp	2017-10-27	6,642,942	5.85	38,861,211
NGM	NGM Biopharmaceuticals Inc	2020-04-08	17,726,978	1.54	27,299,546
RAPT	RAPT Therapeutics Inc	2020-09-22	5,630,497	1.71	9,628,150

Holding Weightings of Peter Svennilson

Peter Svennilson Form 4 Trading Tracker

According to the SEC Form 4 filings, Peter Svennilson has made a total of 4 transactions in Revolution Medicines Inc (RVMD) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in Revolution Medicines Inc is the sale of 76,410 shares on April 28, 2021, which brought Peter Svennilson around $3 Million.

According to the SEC Form 4 filings, Peter Svennilson has made a total of 0 transactions in Immune Design Corp (IMDZ) over the past 5 years. The most-recent trade in Immune Design Corp is the acquisition of 2,681,000 shares on October 27, 2017, which cost Peter Svennilson around $11 Million.

According to the SEC Form 4 filings, Peter Svennilson has made a total of 9 transactions in NGM Biopharmaceuticals Inc (NGM) over the past 5 years, including 9 buys and 0 sells. The most-recent trade in NGM Biopharmaceuticals Inc is the acquisition of 112,602 shares on April 8, 2020, which cost Peter Svennilson around $2 Million.

More details on Peter Svennilson's insider transactions can be found in the Insider Trading History of Peter Svennilson table.

Insider Trading History of Peter Svennilson

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Peter Svennilson Trading Performance

GuruFocus tracks the stock performance after each of Peter Svennilson's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Peter Svennilson is 19.36%. GuruFocus also compares Peter Svennilson's trading performance to market benchmark return within the same time period. The performance of stocks bought by Peter Svennilson within 3 months outperforms 21 times out of 34 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Peter Svennilson's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Peter Svennilson

Average Return

Average return per transaction

Outperforming Transactions

32 out of 34 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	12.49
Relative Return to S&P 500(%)	11.8

Peter Svennilson Ownership Network

Ownership Network List of Peter Svennilson

No Data

Ownership Network Relation of Peter Svennilson

Peter Svennilson Owned Company Details

What does RAPT Therapeutics Inc do?

Who are the key executives at RAPT Therapeutics Inc?

Peter Svennilson is the 10 percent owner of RAPT Therapeutics Inc. Other key executives at RAPT Therapeutics Inc include Chief Scientific Officer Dirk G. Brockstedt , Chief Medical Officer William Ho , and 10 percent owner Column Group Ii, Lp .

RAPT Therapeutics Inc (RAPT) Insider Trades Summary

Over the past 18 months, Peter Svennilson made no insider transaction in RAPT Therapeutics Inc (RAPT). Other recent insider transactions involving RAPT Therapeutics Inc (RAPT) include a net sale of 9,000 shares made by William Ho , and a net sale of 898 shares made by Dirk G. Brockstedt .

In summary, during the past 3 months, insiders sold 0 shares of RAPT Therapeutics Inc (RAPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 9,898 shares of RAPT Therapeutics Inc (RAPT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 9,898 shares.

RAPT Therapeutics Inc (RAPT)'s detailed insider trading history can be found in Insider Trading Tracker table.

RAPT Therapeutics Inc Insider Transactions

No Available Data

What does NGM Biopharmaceuticals Inc do?

Who are the key executives at NGM Biopharmaceuticals Inc?

Peter Svennilson is the director & 10 percent owner of NGM Biopharmaceuticals Inc. Other key executives at NGM Biopharmaceuticals Inc include 10 percent owner Column Group L P , director & 10 percent owner David V Goeddel , and Chief Financial Officer Jean-frederic Viret .

NGM Biopharmaceuticals Inc (NGM) Insider Trades Summary

Over the past 18 months, Peter Svennilson made no insider transaction in NGM Biopharmaceuticals Inc (NGM). Other recent insider transactions involving NGM Biopharmaceuticals Inc (NGM) include a net purchase of 67,893 shares made by Column Group L P , and a net purchase of 26,811 shares made by David V Goeddel .

In summary, during the past 3 months, insiders sold 0 shares of NGM Biopharmaceuticals Inc (NGM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NGM Biopharmaceuticals Inc (NGM) were sold and 94,704 shares were bought by its insiders, resulting in a net purchase of 94,704 shares.

NGM Biopharmaceuticals Inc (NGM)'s detailed insider trading history can be found in Insider Trading Tracker table.

NGM Biopharmaceuticals Inc Insider Transactions

No Available Data

What does Nurix Therapeutics Inc do?

Who are the key executives at Nurix Therapeutics Inc?

Peter Svennilson is the 10 percent owner of Nurix Therapeutics Inc. Other key executives at Nurix Therapeutics Inc include General Counsel Christine Ring , Chief Financial Officer Houte Hans Van , and Chief Scientific Officer Gwenn Hansen .

Nurix Therapeutics Inc (NRIX) Insider Trades Summary

Over the past 18 months, Peter Svennilson made no insider transaction in Nurix Therapeutics Inc (NRIX). Other recent insider transactions involving Nurix Therapeutics Inc (NRIX) include a net sale of 67,327 shares made by Christine Ring , a net sale of 82,022 shares made by Houte Hans Van , and a net sale of 14,703 shares made by Gwenn Hansen .

In summary, during the past 3 months, insiders sold 70,553 shares of Nurix Therapeutics Inc (NRIX) in total and bought 0 shares, with a net sale of 70,553 shares. During the past 18 months, 164,052 shares of Nurix Therapeutics Inc (NRIX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 164,052 shares.

Nurix Therapeutics Inc (NRIX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Nurix Therapeutics Inc Insider Transactions

No Available Data

What does Revolution Medicines Inc do?

Who are the key executives at Revolution Medicines Inc?

Peter Svennilson is the director & 10 percent owner of Revolution Medicines Inc. Other key executives at Revolution Medicines Inc include General Counsel Jeff Cislini , director & See Remarks Mark A Goldsmith , and See Remarks Stephen Michael Kelsey .

Revolution Medicines Inc (RVMD) Insider Trades Summary

Over the past 18 months, Peter Svennilson made no insider transaction in Revolution Medicines Inc (RVMD). Other recent insider transactions involving Revolution Medicines Inc (RVMD) include a net sale of 34,044 shares made by Jeff Cislini , a net sale of 186,391 shares made by Stephen Michael Kelsey , and a net sale of 265,672 shares made by Mark A Goldsmith .

In summary, during the past 3 months, insiders sold 249,942 shares of Revolution Medicines Inc (RVMD) in total and bought 0 shares, with a net sale of 249,942 shares. During the past 18 months, 718,995 shares of Revolution Medicines Inc (RVMD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 718,995 shares.

Revolution Medicines Inc (RVMD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Revolution Medicines Inc Insider Transactions

No Available Data

What does ORIC Pharmaceuticals Inc do?

Who are the key executives at ORIC Pharmaceuticals Inc?

Peter Svennilson is the 10 percent owner of ORIC Pharmaceuticals Inc. Other key executives at ORIC Pharmaceuticals Inc include director & President and CEO Jacob Chacko , Chief Business Officer Pratik S Multani , and Chief Financial Officer Dominic Piscitelli .

ORIC Pharmaceuticals Inc (ORIC) Insider Trades Summary

Over the past 18 months, Peter Svennilson made no insider transaction in ORIC Pharmaceuticals Inc (ORIC). Other recent insider transactions involving ORIC Pharmaceuticals Inc (ORIC) include a net sale of 134,539 shares made by Jacob Chacko , a net sale of 5,282 shares made by Dominic Piscitelli , and a net sale of 5,282 shares made by Pratik S Multani .

In summary, during the past 3 months, insiders sold 0 shares of ORIC Pharmaceuticals Inc (ORIC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 145,103 shares of ORIC Pharmaceuticals Inc (ORIC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 145,103 shares.

ORIC Pharmaceuticals Inc (ORIC)'s detailed insider trading history can be found in Insider Trading Tracker table.

ORIC Pharmaceuticals Inc Insider Transactions

No Available Data

What does Constellation Pharmaceuticals Inc do?

Who are the key executives at Constellation Pharmaceuticals Inc?

Peter Svennilson is the 10 percent owner & other: Managing Partner of Constellation Pharmaceuticals Inc. Other key executives at Constellation Pharmaceuticals Inc include Chief Financial Officer Emma Reeve , 10 percent owner Column Group L P , and See Remarks Karen Valentine .

Constellation Pharmaceuticals Inc (CNST) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Constellation Pharmaceuticals Inc (CNST) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Constellation Pharmaceuticals Inc (CNST) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Constellation Pharmaceuticals Inc (CNST)'s detailed insider trading history can be found in Insider Trading Tracker table.

Constellation Pharmaceuticals Inc Insider Transactions

No Available Data

What does Gritstone Bio Inc do?

Who are the key executives at Gritstone Bio Inc?

Peter Svennilson is the director & 10 percent owner of Gritstone Bio Inc. Other key executives at Gritstone Bio Inc include director & President and CEO Andrew R Allen , See Remarks Matthew Hawryluk , and See Remarks Karin Jooss .

Gritstone Bio Inc (GRTSQ) Insider Trades Summary

Over the past 18 months, Peter Svennilson made no insider transaction in Gritstone Bio Inc (GRTSQ). Other recent insider transactions involving Gritstone Bio Inc (GRTSQ) include a net sale of 1,749 shares made by Vassiliki Economides , a net sale of 24,263 shares made by Andrew R Allen , and a net sale of 13,749 shares made by Karin Jooss .

In summary, during the past 3 months, insiders sold 0 shares of Gritstone Bio Inc (GRTSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 74,769 shares of Gritstone Bio Inc (GRTSQ) were sold and 12,000 shares were bought by its insiders, resulting in a net sale of 62,769 shares.

Gritstone Bio Inc (GRTSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Gritstone Bio Inc Insider Transactions

No Available Data

What does Immune Design Corp do?

Who are the key executives at Immune Design Corp?

Peter Svennilson is the 10 percent owner & other: Managing Partner of Immune Design Corp. Other key executives at Immune Design Corp include 10 percent owner & other: General Partner Column Group Gp, Lp , 10 percent owner Column Group L P , and 10 percent owner & other: General Partner Ponoi Management, Llc .

Immune Design Corp (IMDZ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Immune Design Corp (IMDZ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immune Design Corp (IMDZ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Immune Design Corp (IMDZ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Immune Design Corp Insider Transactions

No Available Data

What does Arcus Biosciences Inc do?

Who are the key executives at Arcus Biosciences Inc?

Peter Svennilson is the 10 percent owner of Arcus Biosciences Inc. Other key executives at Arcus Biosciences Inc include Chief Accounting Officer Alexander Azoy , See Remarks Jennifer Jarrett , and director & 10 percent owner & President Juan C. Jaen .

Arcus Biosciences Inc (RCUS) Insider Trades Summary

Over the past 18 months, Peter Svennilson made no insider transaction in Arcus Biosciences Inc (RCUS). Other recent insider transactions involving Arcus Biosciences Inc (RCUS) include a net sale of 196,515 shares made by Jennifer Jarrett , a net purchase of 16,248,095 shares made by Gilead Sciences Inc , and a net sale of 34,007 shares made by Juan C. Jaen .

In summary, during the past 3 months, insiders sold 0 shares of Arcus Biosciences Inc (RCUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 238,214 shares of Arcus Biosciences Inc (RCUS) were sold and 16,248,095 shares were bought by its insiders, resulting in a net purchase of 16,009,881 shares.

Arcus Biosciences Inc (RCUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arcus Biosciences Inc Insider Transactions

No Available Data

What does eFFECTOR Therapeutics Inc do?

Who are the key executives at eFFECTOR Therapeutics Inc?

Peter Svennilson is the 10 percent owner of eFFECTOR Therapeutics Inc. Other key executives at eFFECTOR Therapeutics Inc include 10 percent owner Sr One Capital Fund I Aggregator Lp , director & 10 percent owner & Chief Executive Officer Christopher B Ehrlich , and Chief Business Officer Mayank Gandhi .

eFFECTOR Therapeutics Inc (EFTR) Insider Trades Summary

Over the past 18 months, Peter Svennilson made no insider transaction in eFFECTOR Therapeutics Inc (EFTR). Other recent insider transactions involving eFFECTOR Therapeutics Inc (EFTR) include a net sale of 609,163 shares made by Sr One Capital Fund I Aggregator Lp ,

In summary, during the past 3 months, insiders sold 0 shares of eFFECTOR Therapeutics Inc (EFTR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 24,367 shares of eFFECTOR Therapeutics Inc (EFTR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 24,367 shares.

eFFECTOR Therapeutics Inc (EFTR)'s detailed insider trading history can be found in Insider Trading Tracker table.

eFFECTOR Therapeutics Inc Insider Transactions

No Available Data

Peter Svennilson Mailing Address

Above is the net worth, insider trading, and ownership report for Peter Svennilson. You might contact Peter Svennilson via mailing address: 1700 Owens Street, Suite 500, San Francisco Ca 94158.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.